Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families. On our News Center, we are celebrating outstanding employees who helped develop this tech.
The Leukemia & Lymphoma Society estimates that by year end, 2024 will have seen 187,740 Americans diagnosed with a blood cancer—or about one person every three minutes.
At Covia facilities, the Community Action Plans (CAPs) exemplify our commitment to proactive community engagement, environmental stewardship, and sustainable development.
Illumina Vice President of Bioinformatics James Han has been in the industry for decades—so he’s witnessed every stride the company has made in that time. “Illumina has worked tirelessly for the last 20 years to improve sequencing,” he says.
James Crowley, manager, transparency and traceability (supply chain) at Cascale, recently participated in the SmartCollab 2024 event, coordinated by Smartex.AI in Porto, Portugal.
Early detection through screening is key to improving lung cancer survivorship – when lung cancer is discovered early enough to be surgically removed before spreading, a patient's chance of surviving five years jumps from 4% to 55%.
CACI International Inc (NYSE: CACI) announced today that it has been named a 5-Star Employer for the fourth consecutive year in the 2024 VETS Indexes Employer Awards.
